SUMMARY
Abstract
Genitourinary syndrome of menopause (GSM) affects nearly 50% of postmenopausal women, yet treatment options are often limited or undesirable due to invasiveness or hormone dependence. This study investigates the effectiveness of MorpheusV, a radiofrequency microneedling device, as a non-hormonal, minimally invasive treatment to alleviate GSM symptoms and improve vaginal health and urinary function.
Conclusion
MorpheusV radiofrequency microneedling provides a safe and effective treatment for genitourinary syndrome of menopause. Patients experienced marked improvements in GSM symptoms with no complications or side effects. These findings support MorpheusV as a valuable, non-hormonal option for vaginal and urinary rejuvenation in postmenopausal women.
TOPICS COVERED
- Evaluation of MorpheusV, an RF microneedling applicator, for intravaginal use
- Study design: 71 patients across two clinics from 2021–2023
- Symptoms addressed include vaginal dryness, dyspareunia, urinary urgency, and frequency
- 50 patients completed six-month follow-up with validated scoring metrics
- Significant improvements in vaginal and urinary symptoms after treatment
- No adverse events reported throughout the study duration
